Category: Allies & Partnerships
Artificial Intelligence and Imaging in Melanoma Care: An Update
An early melanoma diagnosis is more likely to have a positive outcome than one diagnosed later. That’s a fact, but patients often delay having skin lesions checked for a variety of reasons, including long wait times to see a dermatologist—if they can even ﬁnd one close by.
A Message from Our CEO on Veterans Day
On this Veterans Day, we want to express our sincere gratitude and appreciation for the brave individuals who have served and sacrificed for our country. We also want to use today to raise awareness about the unique challenges faced by veterans when it comes to increased risk of developing melanoma,...
Adjuvant Therapy: Is More Better or is Less More?
In 2021 and 2023, the FDA expanded approval of Keytruda and Opdivo, respectively, in the adjuvant setting to include more patients with melanoma — expanding therapeutic options for a greater number of patients. These decision have created tectonic shifts in the field—opening a range of not only treatment options but also discussion points to which the medical, research, and advocacy community are split.
Advancing Research after a Rare Diagnosis: Janet Yannelli's Acral Melanoma Journey
By Renee Orcione, MRA Digital Engagement & Communications Manager | 16 October 2023 In Allies & Partnerships, Melanoma Stories, Science, Treatment
“I had never heard of acral melanoma, even though I’m a nurse,” remarked Janet Yannelli, lifelong Maine resident. Acral melanoma is a rare melanoma subtype that accounts for about 1-3% of cases each year. Acral melanoma forms on the palms, soles of feet, or under nails.
Thriving after Advanced Melanoma at 26: John Elson’s Story
By Renee Orcione, MRA Digital Engagement & Communications Manager | 20 September 2023 In Allies & Partnerships, Melanoma Stories, Treatment
John Elson woke up – on his birthday – and discovered a lump in his neck. The New Yorker wasn’t entirely concerned and initially explained it away as a muscle knot. However, when the lump didn’t go away and he noticed a second one near his armpit, alarm bells started...
Dr. Hussein Tawbi: Opdualag Clinical Trial Updates
In March of 2022, the melanoma community celebrated the FDA approval of nivolumab + relatlimab (brand name Opdualag), a new treatment for patients with metastatic melanoma that combines two different immunotherapies, nivolumab and relatlimab, into one medicine.
Combating Melanoma Brain Metastases and Leptomeningeal Disease
Melanoma is the third most common source of brain metastases, exceeded only by lung and breast cancer. In addition, metastatic melanoma cells have the highest propensity for settling in the brain out of any solid tumor.
Living with Intention with Mucosal Melanoma: Eileen Walther’s Story
In 2018, it had been just over a year since Eileen Walther had been diagnosed with follicular lymphoma, a typically slow-growing form of non-Hodgkin lymphoma that affects white blood cells. After undergoing a chemotherapy regimen known as R-CHOP, she’d been declared cancer free and was ready to get back to...
Compassion, Dignity, & Fashion: Paloma Soledad’s Melanoma Story
By Renee Orcione, MRA Digital Engagement & Communications Manager | 7 August 2023 In Allies & Partnerships, Melanoma Stories
Advanced melanoma challenges patients and families in ways they often could never expect. For New Yorker Paloma Soledad, various side effects from her treatment made it difficult to feel comfortable in her everyday clothing. As a creative artist and designer, she saw this as an opportunity to find a solution...
MRA's Latest Research Report: Reaching for the Stars
Each year, MRA convenes global thought leaders from across the melanoma research community to exchange ideas, report on scientiﬁc successes and challenges, and network and forge new collaborations.